Chester County News and Community Website
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) said it will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026, placing fresh attention on the Philadelphia-based …
Cabaletta Bio Takes Spotlight at Guggenheim Summit as Autoimmune Bet Advances Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) laid out an ambitious 2026 roadmap centered on advancing rese-cel, its experimental CAR T cell therapy for autoimmune diseases, as the company …
Cabaletta Targets 2027 FDA Filing as Autoimmune CAR-T Push Accelerates Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) reported third-quarter results and outlined major clinical and regulatory milestones that position its lead therapy, rese-cel, as a potential first-in-class CAR T …
Cabaletta Bio’s Bold Autoimmune Push Raises Big Questions About the Future of CAR T Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced its participation in several major investor and healthcare conferences through November and December 2025, where company leadership will discuss ongoing progress …
Cabaletta Bio to Present at Key Global Healthcare and Immunology Conferences Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) unveiled promising clinical data from its RESET-Myositis™, RESET-SSc™, and RESET-SLE™ trials evaluating rese-cel (resecabtagene autoleucel), reinforcing its potential to deliver long-lasting, drug-free …
Cabaletta Bio Reports Breakthrough Results in Autoimmune Disease Trials Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced the appointment of Steve Gavel as Chief Commercial Officer, effective immediately. Gavel will oversee all aspects of commercial strategy and execution …
Cabaletta Bio Appoints Steve Gavel as Chief Commercial Officer to Lead Global Launch Strategy for Rese-Cell Therapy Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) presented initial data from its ongoing RESET-PV™ trial evaluating rese-cel (resecabtagene autoleucel, formerly CABA-201) in patients with pemphigus vulgaris (PV) during the …
Cabaletta Bio Presents Early Clinical Data From RESET-PV Trial Showing Rese-Cel Activity Without Preconditioning Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced its participation in several upcoming investor conferences this September, highlighting opportunities to engage with the investment community.
Cabaletta Bio to Present at Multiple Investor Conferences in September Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) reported second-quarter financial results and provided a detailed business update, emphasizing progress toward a 2027 Biologics License Application (BLA) submission for its lead …
Cabaletta Bio Advances Rese-cel Pipeline as BLA Submission for Myositis Nears Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has unveiled new clinical and translational data from its ongoing RESET-Myositis™, RESET-SLE™, and RESET-SSc™ trials. The findings highlight potential breakthroughs for rese-cel …
Cabaletta Bio Reports Promising Data from RESET Trials for Transformative Autoimmune Therapy Read More